The REG3G antibody targets Regenerating Islet-derived Protein 3-gamma (REG3G), a secreted C-type lectin protein belonging to the REG3 family. REG3G is primarily expressed in the gastrointestinal tract, particularly in Paneth cells and goblet cells of the small intestine, as well as in the pancreas. It plays a critical role in innate immunity, acting as an antimicrobial peptide that selectively targets Gram-positive bacteria by binding to peptidoglycan components in their cell walls. This function helps maintain intestinal mucosal barrier integrity and microbiota homeostasis. REG3G is also implicated in tissue repair and cellular proliferation, with elevated expression observed during mucosal injury or inflammation, such as in inflammatory bowel disease (IBD).
Research on REG3G has expanded into its potential roles in metabolic and neoplastic diseases. Studies suggest it may influence insulin sensitivity and β-cell regeneration in diabetes, while its overexpression in certain cancers (e.g., pancreatic, gastric) correlates with tumor progression and poor prognosis. The REG3G antibody is widely used in experimental settings, including Western blotting, immunohistochemistry, and immunofluorescence, to investigate its expression patterns, regulatory mechanisms, and interactions in disease models. Challenges in antibody development include ensuring specificity due to structural similarities within the REG3 family. Recent therapeutic explorations focus on modulating REG3G activity to enhance mucosal healing or counteract pathogenic pathways, highlighting its dual role as a protective agent and a disease-associated biomarker.